5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia
Christopher N Johnson1, Mahmood Ahmed, Neil D Miller
1Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline plc, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK. Christopher.N.Johnson@gsk.com
Abstract:
Several serious neurological and psychiatric disorders are associated with cognitive impairment. Thus, drugs targeting the cognitive symptoms of these diseases would be expected to provide significant benefits to these patient populations. A growing body of preclinical evidence has supported the use of serotonin 5-HT6 receptor antagonism as a promising mechanism for treating cognitive dysfunction. Following the discovery of a new generation of 5-HT6 receptor ligands with improved physicochemical properties, leading to superior brain penetration, additional support for the 5-HT6 hypothesis has been provided by clinical trial data for three molecules in drug development.
Related Concept Videos
Alzheimer's Disease: Treatment
Antidepressant Drugs: MAOIs and Other Agents
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
